Clinical Trial

Published on 10 Jan 2024

RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)

in Cancer Molecular Targets and Therapeutics

Feng Wen
Tianhai Lin
Peng Zhang
Yali Shen

Frontiers in Oncology

doi 10.3389/fonc.2023.1233196

2,932 views
5 citations

Review

Published on 04 Jan 2024

The potential applications of artificially modified exosomes derived from mesenchymal stem cells in tumor therapy

in Cancer Molecular Targets and Therapeutics

Yilin Song
Quanlin Song
Daosheng Hu
Binwen Sun
Mingwei Gao
Xiangnan Liang
Boxin Qu
Lida Suo
Zeli Yin
Liming Wang

Frontiers in Oncology

doi 10.3389/fonc.2023.1299384

1,896 views
2 citations

Case Report

Published on 04 Jan 2024

Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma

in Cancer Molecular Targets and Therapeutics

Marwah Al-Aloosi
Amanda M. Prechtl
Payel Chatterjee
Brady Bernard
Christopher J. Kemp
Rachele Rosati
Robert L. Diaz
Lauren R. Appleyard
Shalini Pereira
Alex Rajewski

Frontiers in Oncology

doi 10.3389/fonc.2023.1267650

3,846 views
3 citations

Original Research

Published on 04 Jan 2024

Development of a cancer metastasis-on-chip assay for high throughput drug screening

in Cancer Molecular Targets and Therapeutics

Lutfiye Yildiz Ozer
Hend Salah Fayed
Johan Ericsson
Ayman Al Haj Zen

Frontiers in Oncology

doi 10.3389/fonc.2023.1269376

5,280 views
4 citations

Original Research

Published on 22 Dec 2023

MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results

in Cancer Molecular Targets and Therapeutics

Felipe F. Souza
Gina D’Amato
Emily Elizabeth Jonczak
Philippos Costa
Jonathan C. Trent
Andrew E. Rosenberg
Raphael Yechieli
H. Thomas Temple
Pradip Pattany
Ty K. Subhawong

Frontiers in Oncology

doi 10.3389/fonc.2023.1286807

1,717 views
1 citation

Review

Published on 22 Dec 2023

Desmoglein-2 as a cancer modulator: friend or foe?

in Cancer Molecular Targets and Therapeutics

Kay K. Myo Min
Charlie B. Ffrench
Barbara J. McClure
Michael Ortiz
Emma L. Dorward
Michael S. Samuel
Lisa M. Ebert
Mỹ G. Mahoney
Claudine S. Bonder

Frontiers in Oncology

doi 10.3389/fonc.2023.1327478

3,184 views

Methods

Published on 21 Dec 2023

The microRNA target site profile is a novel biomarker in the immunotherapy response

in Cancer Molecular Targets and Therapeutics

Yulong Bai
Yujia Li
Yidi Qin
Xinshuo Yang
George C. Tseng
Soyeon Kim
Hyun Jung Park

Frontiers in Oncology

doi 10.3389/fonc.2023.1225221

1,729 views

Original Research

Published on 21 Dec 2023

A tumor-restricted glycoform of podocalyxin is a highly selective marker of immunologically cold high-grade serous ovarian carcinoma

in Cancer Molecular Targets and Therapeutics

Julyanne Brassard
Michael R. Hughes
Pamela Dean
Diana Canals Hernaez
Shelby Thornton
Allyson C. Banville
Julian Smazynski
Mary Warren
Kevin Zhang
Katy Milne

Frontiers in Oncology

doi 10.3389/fonc.2023.1286754

2,729 views
3 citations

Review

Published on 15 Dec 2023

Autophagy-mediated nanomaterials for tumor therapy

in Cancer Molecular Targets and Therapeutics

Zijian Liao
Xiyu Liu
Dianfa Fan
Xingjun Sun
Zhikun Zhang
Pan Wu

Frontiers in Oncology

doi 10.3389/fonc.2023.1194524

2,180 views
2 citations

Review

Published on 13 Dec 2023

Lipid kinases PIP5Ks and PIP4Ks: potential drug targets for breast cancer

in Cancer Molecular Targets and Therapeutics

Yue Jin
Jian Xue

Frontiers in Oncology

doi 10.3389/fonc.2023.1323897

1,992 views
1 citation

Original Research

Published on 13 Dec 2023

Unraveling the safety of adjuvant radiotherapy in prostate cancer: impact of older age and hypofractionated regimens on acute and late toxicity - a multicenter comprehensive analysis

in Cancer Molecular Targets and Therapeutics

Milly Buwenge
Gabriella Macchia
Letizia Cavallini
Annalisa Cortesi
Claudio Malizia
Lorenzo Bianchi
Maria Ntreta
Alessandra Arcelli
Ilaria Capocaccia
Elena Natoli

Frontiers in Oncology

doi 10.3389/fonc.2023.1281432

1,046 views

Case Report

Published on 07 Dec 2023

Anlotinib combined with radiotherapy and chemotherapy for recurrent pelvic osteosarcoma treatment: a case report and literature review

in Cancer Molecular Targets and Therapeutics

Qian Chen
Kai Zheng
Ming Xu
Ning Yan
Gong Hai
Xiuchun Yu

Frontiers in Oncology

doi 10.3389/fonc.2023.1283932

1,108 views
2 citations

Original Research

Published on 07 Dec 2023

Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma

in Cancer Molecular Targets and Therapeutics

Kyaw Zwar Myint
Mireia Sueca-Comes
Pamela Collier
Brinda Balasubramanian
Simran Venkatraman
John Gordan
Abed M. Zaitoun
Abhik Mukherjee
Arvind Arora
Noppadol Larbcharoensub

Frontiers in Oncology

doi 10.3389/fonc.2023.1184900

2,587 views
1 citation

Correction

Published on 07 Dec 2023

Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

in Cancer Molecular Targets and Therapeutics

Yezhe Cheng
Xiaoxi Yuan
Qiang Tian
Xiuying Huang
Yang Chen
Yuzhi Pu
Hu Long
Mingyu Xu
Yafei Ji
Jia Xie

Frontiers in Oncology

doi 10.3389/fonc.2023.1334938

1,756 views

Original Research

Published on 06 Dec 2023

A tumor cell specific Zona Pellucida glycoprotein 3 RNA transcript encodes an intracellular cancer antigen

in Cancer Molecular Targets and Therapeutics

Iman J. Schultz
Yvette Zimmerman
Cathy B. Moelans
Marcin Chrusciel
Jan Krijgh
Paul J. van Diest
Ilpo T. Huhtaniemi
Herjan J. T. Coelingh Bennink

Frontiers in Oncology

doi 10.3389/fonc.2023.1233039

1,405 views

Case Report

Published on 01 Dec 2023

Ribociclib-induced liver injury: a case report

in Cancer Molecular Targets and Therapeutics

Sofia Schaeffer
Christian Lutz
Michael Dobbie
Luigi M. Terracciano
Matthias Matter
Jürg Vosbeck
Markus H. Heim
Christine Bernsmeier

Frontiers in Oncology

doi 10.3389/fonc.2023.1256783

4,663 views
4 citations

Navigation group

Articles

RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2-positive locally advanced muscle-invasive urothelial bladder cancer: a multi-center phase Ib/II study (HOPE-03)

The potential applications of artificially modified exosomes derived from mesenchymal stem cells in tumor therapy

Case report: ex vivo tumor organoid drug testing identifies therapeutic options for stage IV ovarian carcinoma

Development of a cancer metastasis-on-chip assay for high throughput drug screening

MRI T2 mapping assessment of T2 relaxation time in desmoid tumors as a quantitative imaging biomarker of tumor response: preliminary results

Desmoglein-2 as a cancer modulator: friend or foe?

The microRNA target site profile is a novel biomarker in the immunotherapy response

A tumor-restricted glycoform of podocalyxin is a highly selective marker of immunologically cold high-grade serous ovarian carcinoma

Autophagy-mediated nanomaterials for tumor therapy

Lipid kinases PIP5Ks and PIP4Ks: potential drug targets for breast cancer

Unraveling the safety of adjuvant radiotherapy in prostate cancer: impact of older age and hypofractionated regimens on acute and late toxicity - a multicenter comprehensive analysis

Anlotinib combined with radiotherapy and chemotherapy for recurrent pelvic osteosarcoma treatment: a case report and literature review

Preclinical evidence for anaplastic lymphoma kinase inhibitors as novel therapeutic treatments for cholangiocarcinoma

Corrigendum: Preclinical profiles of SKB264, a novel anti-TROP2 antibody conjugated to topoisomerase inhibitor, demonstrated promising antitumor efficacy compared to IMMU-132

A tumor cell specific Zona Pellucida glycoprotein 3 RNA transcript encodes an intracellular cancer antigen

Ribociclib-induced liver injury: a case report